Can low‑dose naltrexone (LDN) be used as a preventive treatment for recurrent migraine in adults?

Low-Dose Naltrexone for Migraine Prevention

Low-dose naltrexone (LDN) is not recommended for migraine prevention and should not be used for this indication. The most recent and comprehensive American College of Physicians (ACP) 2025 guidelines for episodic migraine prevention do not include naltrexone in any form—standard or low-dose—among the evaluated or recommended pharmacologic treatments 1.

Why LDN Is Not Recommended

Absence from Evidence-Based Guidelines

• The 2025 ACP guidelines systematically evaluated all pharmacologic treatments with evidence supporting efficacy for migraine prevention, including off-label medications 1.
• Naltrexone at any dose was not included in the comparative effectiveness review that informed these guidelines, indicating insufficient evidence to support its use 1.
• The guideline explicitly lists evaluated treatments: ACE inhibitors, ARBs, antiseizure medications, β-blockers, CGRP antagonists, CGRP monoclonal antibodies, SSRIs, SNRIs, and tricyclic antidepressants—naltrexone is conspicuously absent 1.

FDA-Approved Indications Only

• Naltrexone is FDA-approved exclusively for alcohol use disorder and opioid use disorder at standard doses of 50 mg daily 2.
• The FDA label contains no mention of migraine prevention or headache disorders as an indication 2.
• Low-dose formulations (1-5 mg) are not FDA-approved and must be compounded, which poses additional access barriers and quality control concerns 3.

Limited and Low-Quality Evidence

• Only a single case report exists describing LDN use for chronic migraines—in a 62-year-old woman with multiple sclerosis who used LDN combined with dietary changes 4.
• This case study provides insufficient evidence to support clinical use, as it involved a single patient with a confounding comorbidity and combined interventions 4.
• Recent scoping reviews acknowledge LDN's use for various painful conditions but note the need for larger clinical trials and proper dosing studies, with no specific evidence supporting migraine prevention 5.

Evidence-Based First-Line Alternatives

Recommended Initial Treatments

The 2025 ACP guidelines provide clear, cost-prioritized recommendations for episodic migraine prevention 1:

Tier 1 (Lowest Cost, Strong Evidence):

• Angiotensin II-receptor blockers (ARBs): Candesartan or telmisartan 1
• β-blockers: Propranolol or metoprolol 1
• Antiseizure medications: Topiramate or valproate 1
• Tricyclic antidepressants: Amitriptyline 1

Tier 2 (Higher Cost, Strong Evidence):

• CGRP monoclonal antibodies: Eptinezumab, erenumab, fremanezumab, or galcanezumab 1
• CGRP antagonists (gepants): Atogepant or rimegepant 1

Treatment Algorithm

1. Start with a low-cost first-line agent (ARB, β-blocker, topiramate, or amitriptyline) based on patient comorbidities and contraindications 1.
2. Initiate at low dose and titrate gradually until desired outcomes are achieved 1.
3. Allow 2-3 months for adequate trial before declaring treatment failure 1, 6.
4. Switch to alternative first-line agent if inadequate response or adverse effects occur 1.
5. Consider CGRP-targeted therapies (monoclonal antibodies or gepants) if multiple first-line agents fail 1.
6. Reserve ACE inhibitors (lisinopril), ARBs (candesartan/telmisartan), or SSRIs (fluoxetine) for patients who cannot tolerate recommended treatments 1.

Critical Pitfalls to Avoid

Do Not Use LDN for Migraine

• There is no evidence supporting LDN for migraine prevention in any published guideline or systematic review 1, 6.
• Using LDN diverts patients from evidence-based treatments that demonstrably reduce migraine frequency, disability, and emergency department visits 1.
• Compounded LDN lacks FDA oversight and may have variable quality and potency 3.

Recognize Contraindications to Standard Naltrexone

• Patients requiring opioid-containing medications (analgesics, antitussives, antidiarrheals) cannot use naltrexone, as it blocks opioid effects 2.
• Naltrexone carries hepatotoxicity risk, particularly at doses above 50 mg, though this is less characterized at low doses 2.
• Patients must be opioid-free for 7-10 days before initiating naltrexone to avoid precipitated withdrawal 2.

Emphasize Adherence and Realistic Expectations

• Improvement with preventive therapy occurs gradually over weeks to months, not immediately 1.
• Patients should maintain headache diaries to track efficacy and identify analgesic overuse 1.
• Cost considerations are paramount—prescribe the least expensive effective medication first 1.

Special Populations

Pregnancy and Breastfeeding

• Discuss adverse effects of all pharmacologic treatments during pregnancy and lactation with patients of childbearing potential 1.
• Naltrexone is not recommended during pregnancy due to lack of safety data 2.

Chronic Migraine (≥15 Headache Days/Month)

• For chronic migraine specifically, onabotulinumtoxinA is an evidence-based option with a weak-for recommendation, reducing headache days by 1.8 days/month compared to placebo 7.
• OnabotulinumtoxinA is not recommended for episodic migraine and should only be considered after failure of multiple first-line preventive therapies 7.